Eisai Inc

We track 4 ClinicalTrials.gov studies led by Eisai Inc. The portfolio skews toward Phase 2 (2 trials).

4 clinical trials sponsored by Eisai Inc.

Pipeline by Phase

PhaseTrialsDistribution
Phase 2 2
50%
Phase 3 2
50%

Trial Status Breakdown

Trials by Eisai Inc

An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an Anti-human Epidermal Growth Factor Receptor 2 (Anti-HER2) Antibody-drug Conjugate (ADC), in Previously Treated Subjects With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

NCT06188559 · ACTIVE NOT RECRUITING · Phase 2

AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)

NCT04468659 · ACTIVE NOT RECRUITING · Phase 3

A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

NCT03887455 · ACTIVE NOT RECRUITING · Phase 3

A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

NCT01767311 · COMPLETED · Phase 2

Frequently Asked Questions

How many clinical trials does Eisai Inc sponsor?

Eisai Inc currently sponsors 4 clinical trials tracked on ReadTheTrial. These span Phase 2, Phase 3.

What conditions does Eisai Inc research?

Eisai Inc conducts research across multiple therapeutic areas. Browse the trial listings for details.

Is Eisai Inc recruiting for clinical trials?

Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.

Explore More